ARTICLE

EFFECT OF MYOINOSITOL SUPPLEMENTATION ON ANTHROPOMETRIC PARAMETERS AMONG PCOS WOMEN IN GUJRANWALA

  1. HOME
  2. ARTICLE

03 Pages : 16-28

http://dx.doi.org/10.31703/giidr.2024(IX-III).03      10.31703/giidr.2024(IX-III).03      Published : Sep 2024

Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala

Abstract

    Polycystic Ovarian Syndrome Metabolic and endocrine disorder PCOS affects many premenopausal women. Ovarian dysfunction and androgen excess symptoms and signs explain it. High BMI and WHR, or visceral obesity, are more common in PCOS women. The study aims to evaluate myo-inositol (MI) supplementation on anthropometric measurements in Gujranwala PCOS women. Participants were selected from Life Care Hospital, Gujranwala. Each of the three groups included 30 members. The 3-month intervention concluded. The participants were instructed to consume 2000mg of myo-inositol at night. At the 0, 30, 60, and 90th days of study, weight, height, BMI, and waist-to-hip ratio were measured. The study ended with a comparison of pre-and post-intervention findings. The study found that Myo-inositol considerably(p<0.0001) improved anthropometric parameters. Weight, BMI, and WHR decreased among participants, although significant differences exist between groups(P<0.005) despite minimal variation in mean values. This study found that feeding PCOS women MI decreased weight, BMI, and WHR.

    PCOS, Myo-Inositol, Weight, Anthropometrics, BMI, WHR, Supplementation

    (1) Mahnoor
    Consultant Dietitian and Nutritionist, NUR International University, Lahore, Punjab, Pakistan.
Fulltext PDF

References

  • Andriana, A., & Sumarni, S. (2019). The effectiveness of acupuncture on women with polycystic ovary syndrome: Systematic literature review. In Proceedings of the International Conference on Applied Science and Heal

  • Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022). Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. International Journ

  • Broughton

  • Broughton, D. E., & Moley, K. H. (2017). Obesity and female infertility: potential mediators of obesity’s impact. Fertility and Sterility, 107(4), 840–847.

  • Bruni, V., Capozzi, A., & Lello, S. (2021). The Role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development: the State of the Art. Reproductive Sciences, 29(3), 668–679. <

  • Burgert, T. S., & Paprocki, E. (2022). Managing PCOS in the adolescent polycystic ovary syndrome. In Polycystic ovary syndrome (pp. 193-204). Springer.

  • Caanen, M. R., Peters, H. E., Van De Ven, P. M., Jüttner, A. M. F. M., Laven, J. S. E., Van Hooff, M. H. A., & Lambalk, C. B. (2020). Anti-Müllerian hormone levels in adolescence in relation to long-term follow-up for

  • Cappelli, V., Musacchio, M. C., Bulfoni, A., Morgante, G., & De Leo, V. (2017). Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS. European review for medical and pharmacolo

  • Crisosto, N., De Guevara, A. L., Echiburú, B., Maliqueo, M., Cavada, G., Codner, E., Paez, F., & Sir-Petermann, T. (2018). Higher luteinizing hormone levels associated with antimüllerian hormone in postmenarchal daugh

  • DiNicolantonio, J. J., & O’Keefe, J. H. (2022). Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart, 9(1), e001989.

  • Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284.

  • Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020). Inositols in Polycystic Ovary Syndrome: An overview on the

  • Fong, S. L., Douma, A., & Verhaeghe, J. (2021). Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): how to achieve weight loss in overweight and ob

  • Heidarzadehpilehrood, R., Pirhoushiaran, M., Abdollahzadeh, R., Osman, M. B., Sakinah, M., Nordin, N., & Hamid, H. A. (2022). A review on CYP11A1, CYP17A1, and CYP19A1 polymorphism studies: candidate susceptibility ge

  • Himabindu, Y., Kiranmayee, D., Kavya, K., Sriharibabu, M., Madhuri, G. J., & Venu, S. (2017). Correlations between anthropometry and lipid profile in women with PCOS. Journal of Human Reproductive Sciences,

  • Huang, R., Zhao, P., Xu, J., Liu, D., Luo, F., & Dai, Y. (2017). Effects of placebo‐controlled insulin‐sensitizing drugs on hormonal parameters in polycystic ovary syndrome patients: A network meta‐analysis. Journa

  • Huddleston, H. G., & Dokras, A. (2022). Diagnosis and treatment of polycystic ovary Syndrome. JAMA, 327(3), 274.

  • Ibáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., Rudaz, C. G., Hoeger, K. M., López-Bermejo, A., Ong, K., Peña, A. S., R

  • Jin, P., & Xie, Y. (2017). Treatment strategies for women with polycystic ovary syndrome. Gynecological Endocrinology, 34(4), 272–277.

  • Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022). Polycystic ovary syndrome. The Lancet Diabetes & Endocrinology, 10(9), 668–

  • Kh, M. M., & Boboev, K. (2022). Modern aspects of etiology, diagnosis, and treatment of polycystic ovarian syndrome. European Journal of Modern Medicine and Practice, 2(8), 86-93.

  • Maqbool, M., Gani, I., & Geer, M. (2019). Polycystic ovarian syndrome-a multifaceted disease: a review. International Journal of Pharmaceutical Sciences and Research, 10(3).

  • Meczekalski, B., Niwczyk, O., Kostrzak, A., Maciejewska-Jeske, M., Bala, G., & Szeliga, A. (2023). PCOS in Adolescents—Ongoing Riddles in Diagnosis and Treatment. Journal of Clinical Medicine, 12(3), 122

  • Medina, G., Vera-Lastra, O., Peralta-Amaro, A. L., Jiménez-Arellano, M. P., Saavedra, M. A., Cruz-Domínguez, M. P., & Jara, L. J. (2018). Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacological Res

  • Moghetti, P., & Tosi, F. (2020). Insulin resistance and PCOS: chicken or egg? Journal of Endocrinological Investigation, 44(2), 233–244.

  • Nehra, J., Kaushal, J., Singhal, S. R., & Ghalaut, V. S. (2017). Comparison of myo-inositol versus metformin on anthropometric parameters in polycystic ovarian syndrome in women. Education, 11(22), 8.

  • Pkhaladze, L., Russo, M., Unfer, V., Nordio, M., Basciani, S., & Khomasuridze, A. (2021). Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives. DOAJ (DOAJ: Directory

  • Pundir, J., Charles, D., Sabatini, L., Hiam, D., Jitpiriyaroj, S., Teede, H., Coomarasamy, A., Moran, L., & Thangaratinam, S. (2018). Overview of systematic reviews of non-pharmacological interventions in women with p

  • Rosenfield, R. L., & Ehrmann, D. A. (2016). The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews, 37(5), 467–52

  • Shan, H., Luo, R., Guo, X., Li, R., Ye, Z., Peng, T., Liu, F., & Yang, Z. (2022). Abnormal endometrial receptivity and oxidative stress in polycystic ovary syndrome. Frontiers in Pharmacology, 13.

  • Wekker, V., Van Dammen, L., Koning, A., Heida, K. Y., Painter, R. C., Limpens, J., Laven, J. S. E., Van Lennep, J. E. R., Roseboom, T. J., & Hoek, A. (2020). Long-term cardiometabolic disease risk in women with PCOS:

  • Witchel, S. F., Burghard, A. C., Tao, R. H., & Oberfield, S. E. (2019). The diagnosis and treatment of PCOS in adolescents: an update. Current Opinion in Pediatrics, 31(4), 562–569. <

  • Zhang, Y., Luo, S., Gong, Z., Feng, X., Wang, Z., Zhu, H., & Wang, Y. (2018). Improvement of hyperandrogenism, oligo-ovulation, and ovarian morphology in a patient with polycystic ovary syndrome: p

  • Zulfiqar, S., Tahir, S., Gulraiz, S., Razzaq, M. A., Abid, A., Shahid, T., Babar, A., Rehman, B., Rafique, H., Noor, S., & Anjum, I. (2022). Investigation of Prevalence and Awareness of Polycystic Ovary Syndrome among

Cite this article

APA

    APA : Mahnoor. (2024). Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala. Global Immunological & Infectious Diseases Review, IX(III), 16-28. https://doi.org/10.31703/giidr.2024(IX-III).03

CHICAGO

    CHICAGO : Mahnoor, . 2024. "Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala." Global Immunological & Infectious Diseases Review, IX (III): 16-28 doi: 10.31703/giidr.2024(IX-III).03

HARVARD

    HARVARD : MAHNOOR. 2024. Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala. Global Immunological & Infectious Diseases Review, IX, 16-28.

MHRA

    MHRA : Mahnoor, . 2024. "Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala." Global Immunological & Infectious Diseases Review, IX: 16-28

MLA

    MLA : Mahnoor, . "Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala." Global Immunological & Infectious Diseases Review, IX.III (2024): 16-28 Print.

OXFORD

    OXFORD : Mahnoor, (2024), "Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala", Global Immunological & Infectious Diseases Review, IX (III), 16-28

TURABIAN

    TURABIAN : Mahnoor, . "Effect of Myo-Inositol Supplementation on Anthropometric Parameters among PCOS Women in Gujranwala." Global Immunological & Infectious Diseases Review IX, no. III (2024): 16-28. https://doi.org/10.31703/giidr.2024(IX-III).03